Open AccessTreatment of EGFR positive lung adenocarcinoma in a heart transplanted patient
Author(s) -
Ana Hečimović,
Andrea Vukić Dugac,
Mateja Janković Makek,
Maja Čikeš,
Miroslav Samaržija,
Marko Jakopović
Publication year - 2019
Publication title -
monaldi archives for chest disease. pulmonary series/monaldi archives for chest disease/monaldi archives for chest disease. cardiac series
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.196
H-Index - 46
eISSN - 2465-101X
pISSN - 1122-0643
DOI - 10.4081/monaldi.2019.1023
Subject(s) - erlotinib , medicine , lung cancer , adenocarcinoma , incidence (geometry) , oncology , lung , lung transplantation , population , adenocarcinoma of the lung , drug , cancer , epidermal growth factor receptor , pharmacology , physics , environmental health , optics
Lung cancer incidence in heart transplant patients is higher than in general population and correlates with smoking history. EGFR-mutations are more frequent in adenocarcinoma and among non-smoking women but incidence in solid organ transplanted patients is still not known. We present case of a 65-year-old ex-smoker male with history of heart transplantation and EGFR positive metastatic lung adenocarcinoma. At admission he was in a severe clinical condition and treatment with erlotinib was started. Initially he had good clinical and radiologic response to treatment with only grade 1 side effects. Data about drug interactions between cyclosporine and erlotinib are insufficient but we have to take this interaction into consideration during treatment because both drugs are substrates and inhibitors of CYP34A. In our case erlotinib was safe and well tolerated drug, there were no relevant toxicity, but close monitoring and dose reduction of cyclosporine was needed.